FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3195995680> ?p ?o ?g. }

• W3195995680 abstract "The incidence of bladder cancer (BCa) in male is approximately three to four times higher than in female, but the oncological outcomes in female patients with BCa are significantly worse than in male patients. Although many biomarkers have been identified in recent decades to predict the prognosis of BCa patients, few of them are able to distinguish the prognosis of BCa patients with gender difference. Aromatase encoded by the CYP19A1 gene catalyzes the conversion of androgens to estrogens. In this study, we investigate the prognosis significance of CYP19A1 expression considering the gender difference in BCa patients from four available public databases.Four available public databases of BCa, including GSE13507, TCGA-BLCA, E-MTAB-4321, and E-MTAB-1803, were utilized in this analysis. The overall survival (OS) and progression-free survival (PFS) in different stages and genders were evaluated using the Kaplan-Meier analysis based on the optimal cut-off values of CYP19A1 expression. Then, Gene Set Enrichment Analysis (GSEA) were further performed to explore the potential biologic pathways by altering CYP19A1 expression in BCa patients.The results showed that patients with high CYP19A1 expression had a poorer outcome compared with those with low expression in both BCa cohorts in general. Higher CYP19A1 expression in male patients were significantly associated with shorter survival for either non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC). However, female NMIBC patients with high CYP19A1 expression were identified to have a better prognosis, whereas high CYP19A1 expression in female MIBC patients were significantly associated with poorer survival. The result of the GSEA showed that different outcomes in female and male patients with NMIBC were related to the interaction of CYP19A1 and the cell-cycle-related pathways.These findings demonstrated that CYP19A1 expression might have a potential role in distinguishing the prognosis of female BCa patients dependent on tumor stage. Our results provide new insights for aromatase-mediated BCa therapy." @default.
• W3195995680 created "2021-08-30" @default.
• W3195995680 creator A5000524879 @default.
• W3195995680 creator A5006115265 @default.
• W3195995680 creator A5012938558 @default.
• W3195995680 creator A5020494448 @default.
• W3195995680 creator A5022610561 @default.
• W3195995680 creator A5036524442 @default.
• W3195995680 creator A5037045029 @default.
• W3195995680 creator A5059599037 @default.
• W3195995680 creator A5065406086 @default.
• W3195995680 creator A5070564089 @default.
• W3195995680 creator A5078099916 @default.
• W3195995680 creator A5078852225 @default.
• W3195995680 creator A5088394795 @default.
• W3195995680 creator A5088897280 @default.
• W3195995680 date "2021-01-01" @default.
• W3195995680 modified "2023-10-12" @default.
• W3195995680 title "The prognostic roles of CYP19A1 expression in bladder cancer patients of different genders" @default.
• W3195995680 cites W1271572098 @default.
• W3195995680 cites W1927418190 @default.
• W3195995680 cites W1966129042 @default.
• W3195995680 cites W1988066591 @default.
• W3195995680 cites W1994282614 @default.
• W3195995680 cites W1997112627 @default.
• W3195995680 cites W1998458200 @default.
• W3195995680 cites W1998756818 @default.
• W3195995680 cites W2018335025 @default.
• W3195995680 cites W2023942118 @default.
• W3195995680 cites W2043009300 @default.
• W3195995680 cites W2047518704 @default.
• W3195995680 cites W2055131068 @default.
• W3195995680 cites W2098876067 @default.
• W3195995680 cites W2098995301 @default.
• W3195995680 cites W2099423538 @default.
• W3195995680 cites W2115156555 @default.
• W3195995680 cites W2138312679 @default.
• W3195995680 cites W2142937869 @default.
• W3195995680 cites W2144896165 @default.
• W3195995680 cites W2398544696 @default.
• W3195995680 cites W2398556959 @default.
• W3195995680 cites W2573152477 @default.
• W3195995680 cites W2729162541 @default.
• W3195995680 cites W2763670669 @default.
• W3195995680 cites W2767348608 @default.
• W3195995680 cites W2800511975 @default.
• W3195995680 cites W2889454927 @default.
• W3195995680 cites W2889646458 @default.
• W3195995680 cites W2891366583 @default.
• W3195995680 cites W2892569486 @default.
• W3195995680 cites W2901043405 @default.
• W3195995680 cites W2920600229 @default.
• W3195995680 cites W2946288302 @default.
• W3195995680 cites W2951071083 @default.
• W3195995680 cites W2982766258 @default.
• W3195995680 cites W2984881695 @default.
• W3195995680 cites W2989667815 @default.
• W3195995680 cites W3005569325 @default.
• W3195995680 cites W4211115520 @default.
• W3195995680 cites W4251731689 @default.
• W3195995680 cites W2782468886 @default.
• W3195995680 doi "https://doi.org/10.21037/tau-21-400" @default.
• W3195995680 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8511542" @default.
• W3195995680 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34733654" @default.
• W3195995680 hasPublicationYear "2021" @default.
• W3195995680 type Work @default.
• W3195995680 sameAs 3195995680 @default.
• W3195995680 citedByCount "1" @default.
• W3195995680 countsByYear W31959956802023 @default.
• W3195995680 crossrefType "journal-article" @default.
• W3195995680 hasAuthorship W3195995680A5000524879 @default.
• W3195995680 hasAuthorship W3195995680A5006115265 @default.
• W3195995680 hasAuthorship W3195995680A5012938558 @default.
• W3195995680 hasAuthorship W3195995680A5020494448 @default.
• W3195995680 hasAuthorship W3195995680A5022610561 @default.
• W3195995680 hasAuthorship W3195995680A5036524442 @default.
• W3195995680 hasAuthorship W3195995680A5037045029 @default.
• W3195995680 hasAuthorship W3195995680A5059599037 @default.
• W3195995680 hasAuthorship W3195995680A5065406086 @default.
• W3195995680 hasAuthorship W3195995680A5070564089 @default.
• W3195995680 hasAuthorship W3195995680A5078099916 @default.
• W3195995680 hasAuthorship W3195995680A5078852225 @default.
• W3195995680 hasAuthorship W3195995680A5088394795 @default.
• W3195995680 hasAuthorship W3195995680A5088897280 @default.
• W3195995680 hasBestOaLocation W31959956801 @default.
• W3195995680 hasConcept C10515644 @default.
• W3195995680 hasConcept C120665830 @default.
• W3195995680 hasConcept C121332964 @default.
• W3195995680 hasConcept C121608353 @default.
• W3195995680 hasConcept C126322002 @default.
• W3195995680 hasConcept C143998085 @default.
• W3195995680 hasConcept C2776166826 @default.
• W3195995680 hasConcept C2780352672 @default.
• W3195995680 hasConcept C29456083 @default.
• W3195995680 hasConcept C3019894029 @default.
• W3195995680 hasConcept C530470458 @default.
• W3195995680 hasConcept C60644358 @default.
• W3195995680 hasConcept C61511704 @default.
• W3195995680 hasConcept C71924100 @default.
• W3195995680 hasConcept C86803240 @default.

• next